Intellia Therapeutics Inc sell The Goldman Sachs Group, Inc.
Start price
28.02.25
/
50%
€9.21
Target price
28.02.26
€8.65
Performance (%)
47.32%
Price
13:42
€13.57
Summary
This prediction is currently active. The price for Intellia Therapeutics Inc has massively increased, which is bad news for the SELL prediction by The_Goldman_Sachs_Gr. This prediction currently runs until 28.02.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | 32.064% | 32.064% |
| iShares Core DAX® | -1.673% | 2.237% |
| iShares Nasdaq 100 | -1.346% | 0.290% |
| iShares Nikkei 225® | -1.529% | 5.863% |
| iShares S&P 500 | -1.702% | 0.697% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "sell" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat